Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CCCC C4 Therapeutics	$2.55 -2.5%	$2.03	$1.09 ▼ $7.22	$180.42M	2.97	1.43 million shs	414,282 shs
ENTA Enanta Pharmaceuticals	$8.61 -2.5%	$7.49	$4.09 ▼ $13.43	$184.26M	0.88	279,441 shs	51,361 shs
MRMD MariMed	$0.11 -0.4%	$0.10	$0.07 ▼ $0.23	$43.73M	3.02	546,695 shs	2.49 million shs
NLTX Neoleukin Therapeutics	$19.99 +1.2%	$20.30	$2.03 ▼ $14.36	$187.87M	1.11	50,104 shs	134,942 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CCCC C4 Therapeutics	0.00%	+6.10%	+15.49%	+89.13%	-60.69%
ENTA Enanta Pharmaceuticals	0.00%	+10.38%	+19.32%	+51.98%	-32.54%
MRMD MariMed	0.00%	+2.18%	-3.10%	+51.89%	-49.37%
NLTX Neoleukin Therapeutics	0.00%	-2.54%	-12.36%	+15.68%	-42.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CCCC C4 Therapeutics	1.4734 of 5 stars	3.2	2.0	0.0	0.0	0.0	1.7	0.6
ENTA Enanta Pharmaceuticals	3.5057 of 5 stars	3.5	0.0	0.0	4.7	1.4	2.5	0.0
MRMD MariMed	0.914 of 5 stars	0.0	5.0	0.0	0.0	1.1	0.8	0.6
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CCCC C4 Therapeutics	2.33	Hold	$8.00	214.34% Upside
ENTA Enanta Pharmaceuticals	3.00	Buy	$21.67	151.62% Upside
MRMD MariMed	4.00	Strong Buy	N/A	N/A
NLTX Neoleukin Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest MRMD, NLTX, ENTA, and CCCC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	MRMD MariMed	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/12/2025	ENTA Enanta Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$24.00 ➝ $25.00
7/28/2025	ENTA Enanta Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
6/3/2025	ENTA Enanta Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$23.00 ➝ $24.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CCCC C4 Therapeutics	$35.58M	5.09	N/A	N/A	$3.06 per share	0.83
ENTA Enanta Pharmaceuticals	$64.81M	2.84	N/A	N/A	$6.08 per share	1.42
MRMD MariMed	$157.96M	0.28	$0.02 per share	5.21	$0.16 per share	0.70
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	$11.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CCCC C4 Therapeutics	-$105.32M	-$1.58	N/A	N/A	N/A	-325.88%	-53.91%	-33.26%	10/30/2025 (Estimated)
ENTA Enanta Pharmaceuticals	-$116.04M	-$4.32	N/A	N/A	N/A	-141.98%	-89.02%	-27.28%	N/A
MRMD MariMed	-$12.16M	-$0.03	N/A	∞	N/A	-10.14%	-10.52%	-3.10%	11/5/2025 (Estimated)
NLTX Neoleukin Therapeutics	-$57.56M	-$3.11	N/A	∞	N/A	N/A	-37.22%	-30.91%	N/A

Latest MRMD, NLTX, ENTA, and CCCC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2025	Q3 2025	ENTA Enanta Pharmaceuticals	-$1.25	-$0.85	+$0.40	-$0.85	$16.21 million	$18.31 million
8/7/2025	Q2 2025	CCCC C4 Therapeutics	-$0.38	-$0.37	+$0.01	-$0.37	$5.24 million	$6.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CCCC C4 Therapeutics	N/A	N/A	N/A	N/A	N/A
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRMD MariMed	N/A	N/A	N/A	N/A	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CCCC C4 Therapeutics	N/A	5.06	5.06
ENTA Enanta Pharmaceuticals	N/A	5.00	5.00
MRMD MariMed	1.25	1.12	0.36
NLTX Neoleukin Therapeutics	N/A	15.33	15.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CCCC C4 Therapeutics	78.81%
ENTA Enanta Pharmaceuticals	94.99%
MRMD MariMed	0.18%
NLTX Neoleukin Therapeutics	52.37%

Insider Ownership

Company	Insider Ownership
CCCC C4 Therapeutics	8.73%
ENTA Enanta Pharmaceuticals	13.89%
MRMD MariMed	18.99%
NLTX Neoleukin Therapeutics	1.58%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CCCC C4 Therapeutics	150	71.17 million	64.96 million	Optionable
ENTA Enanta Pharmaceuticals	160	21.38 million	18.41 million	Optionable
MRMD MariMed	260	390.44 million	316.29 million	Not Optionable
NLTX Neoleukin Therapeutics	90	9.40 million	9.25 million	No Data

MRMD, NLTX, ENTA, and CCCC Headlines

Recent News About These Companies

Neoleukin Therapeutics (NASDAQ:NLTX) Shares Down 5.6% - Should You Sell?

August 15, 2025 | marketbeat.com

(NGNE) Proactive Strategies

October 18, 2024 | news.stocktradersdaily.comN

Neurogene concludes merger deal with Neoleukin Therapeutics

December 20, 2023 | pharmaceutical-technology.comP

Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?

December 20, 2023 | finance.yahoo.com

Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split

December 14, 2023 | finance.yahoo.com

Neoleukin Therapeutics Stock (NASDAQ:NLTX) Dividends: History, Yield and Dates

December 4, 2023 | benzinga.com

Pre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…

October 5, 2023 | markets.businessinsider.com

Neoleukin Therapeutics, Inc.: Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

September 26, 2023 | finanznachrichten.de

Neoleukin Thera (NASDAQ: NLTX) should be up 500% - it’s actually up 7%

September 26, 2023 | dhakatribune.comD

Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

September 22, 2023 | finance.yahoo.com

Investing in Neoleukin Therapeutics Inc. [NLTX]: What You Must Know

August 21, 2023 | knoxdaily.comK

Neoleukin Therapeutics Recent Insider Activity

August 18, 2023 | benzinga.com

BAKER BROS. ADVISORS LP Reduces Stake in Neoleukin Therapeutics Inc

August 18, 2023 | finance.yahoo.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, CCF, NLTX, SCU

August 8, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AJX, DEN, FREQ, NLTX

August 1, 2023 | markets.businessinsider.com

Redmile Group, LLC Boosts Stake in Neoleukin Therapeutics Inc

July 28, 2023 | finance.yahoo.com

Moore Kuehn Encourages AMNB, SCU, NLTX, and PRDS Investors to Contact Law Firm

July 26, 2023 | benzinga.com

Analysts review Neoleukin Therapeutics Inc.’s rating

July 26, 2023 | knoxdaily.comK

ALERT: The M&A Class Action Firm Continues Investigating the Merger – SCU, NLTX, HCCI, CCF

July 24, 2023 | kentuckytoday.comK

Baker Bros. Advisors Now Owns 19.99% of Neoleukin Therapeutics

July 24, 2023 | 247wallst.com

An Analysis of Neoleukin Therapeutics Inc. (NLTX)’s Potential Price Growth

July 19, 2023 | knoxdaily.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MRMD, NLTX, ENTA, and CCCC Company Descriptions

C4 Therapeutics NASDAQ:CCCC

$2.54 -0.07 (-2.49%)

As of 03:35 PM Eastern

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Enanta Pharmaceuticals NASDAQ:ENTA

$8.61 -0.22 (-2.48%)

As of 03:33 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

MariMed OTCMKTS:MRMD

$0.11 0.00 (-0.36%)

As of 03:13 PM Eastern

MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty's Eddies brand and ice creams under Emack & Bolio's brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.

Neoleukin Therapeutics NASDAQ:NLTX

$19.99 +0.24 (+1.22%)

As of 08/22/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time